China Recombinant Hepatitis B Vaccine For Virus Infection Prevention Manufacturer, Supplier, Factory

AIM Honesty Biopharmaceutical Co., Ltd., a leading China-based manufacturer of recombinant vaccines, offers the Recombinant Hepatitis B Vaccine For Virus Infection Prevention—a product developed using the first domestically adopted Hansenula polymorpha expression platform. With nearly 500 million doses administered across China and a production capacity of 45 million doses per year, this vaccine delivers robust protection against hepatitis B virus (HBV) infection, a disease that affects over 296 million people globally and is a major cause of liver cirrhosis and hepatocellular carcinoma. The 10 μg formulation provides effective immunization for all age groups, including newborns of HBsAg-positive mothers, healthcare workers, and high-risk populations, making it a trusted choice for national immunization programs and international procurement.

Addressing the Global HBV Burden

Chronic hepatitis B remains a critical public health challenge worldwide, with an estimated 296 million people living with chronic infection and approximately 820,000 deaths annually from HBV-related liver disease. The Recombinant Hepatitis B Vaccine For Virus Infection Prevention directly addresses this burden by offering a highly immunogenic and safe intervention. Unlike many vaccines that require higher doses or multiple boosters for certain groups, this product's 10 μg dose achieves protective antibody levels in over 95% of healthy recipients after a complete three-dose series. This efficacy is particularly vital for newborns, where timely vaccination can reduce the risk of chronic carriage by more than 90%.

● Neonatal protection – crucial for breaking mother-to-child transmission, especially when combined with hepatitis B immunoglobulin.

● Healthcare worker safety – provides reliable immunity for those with occupational blood exposure.

● Travel and endemic area protection – ideal for individuals visiting or residing in regions with high HBV prevalence.

By choosing this vaccine, immunization program managers and procurement officers secure a product with a proven track record in real-world settings, backed by nearly two decades of market experience and continuous post-marketing surveillance.

Engineered for Superior Immunogenicity

The Recombinant Hepatitis B Vaccine leverages the Hansenula polymorpha yeast expression system—an advanced platform that yields antigen with higher purity and more native conformational epitopes compared to traditional Saccharomyces cerevisiae or CHO cell systems. This structural fidelity translates into stronger and more durable immune responses. The proprietary RECVAX® adjuvant technology further enhances performance through in situ adsorption, creating an "antigen depot" that steadily releases the immunogen over time, thereby prolonging antigen presentation and boosting both humoral and cellular immunity.

Key immunological advantages include:

● High seroconversion rates: In clinical studies, over 98% of vaccinated individuals achieved anti-HBs titers >10 mIU/mL after the full course.

● Long-lasting memory: Follow-up data show protective antibody levels persist for at least 10 years in the majority of recipients, reducing the need for frequent boosters.

● Enhanced cellular response: The Hansenula polymorpha platform induces stronger T-cell activation, which is critical for clearing virus-infected cells and providing sterilizing immunity.

Comparative Analysis: Platform Advantages

When evaluating hepatitis B vaccines, procurement specialists often compare different expression systems. The following table highlights why the Recombinant Hepatitis B Vaccine stands out in terms of purity, safety, and immunogenicity.

This comparison clearly demonstrates that the Hansenula polymorpha platform offers the best combination of safety, purity, and efficacy—a critical consideration for programs aiming to achieve high coverage and long-term protection with minimal adverse events.

Target Populations and Clinical Applications

The Recombinant Hepatitis B Vaccine For Virus Infection Prevention is indicated for all susceptible individuals, with a focus on high-priority groups where the risk of infection and disease progression is greatest. Clinical guidelines and national immunization programs consistently recommend this vaccine for:

● Newborns, especially those born to HBsAg-positive mothers – timely administration within 24 hours of birth, combined with HBIG, reduces transmission by over 95%.

● Healthcare and laboratory personnel – those with frequent blood contact are at elevated risk, and vaccination ensures occupational safety.

● Individuals with high-risk sexual behavior, injection drug users, and household contacts of chronic carriers – these populations account for a significant proportion of new infections in many countries.

● Patients with chronic liver disease, renal failure on hemodialysis, or HIV infection – these groups often have suboptimal responses to other vaccines, but the Hansenula polymorpha product shows superior performance due to its enhanced adjuvant system.

Real-world application data from China, where this vaccine covers nearly 80% of newborns, demonstrate its effectiveness in reducing childhood HBV carrier rates to below 1% in immunized cohorts, a remarkable achievement in public health.

Long-Term Immune Persistence Evidence

One of the most compelling attributes of the Recombinant Hepatitis B Vaccine is its enduring protection. A landmark study led by Academician Li Lanjuan evaluated booster responses in children aged 5–15 years who received various hepatitis B vaccines. After a 0-1-6 month booster series with 10 μg RECVAX® (Hansenula polymorpha), the anti-HBs seropositive rates at 1, 5, and 8 years post-booster reached 83.4%—the highest among all four vaccines assessed. This demonstrates not only the vaccine's ability to mount a strong anamnestic response but also its capacity to maintain long-term immune memory, reducing the frequency of boosters and overall program costs.

Furthermore, the vaccine's purity profile minimizes the risk of adverse reactions, ensuring high acceptance and adherence among recipients. Over 20 years of market experience and nearly 500 million doses distributed have solidified its safety record, with no vaccine-related serious adverse events reported in routine surveillance.

Manufacturing Excellence and Quality Assurance

AIM Honesty Biopharmaceutical Co., Ltd. operates a dedicated 11,000-square-meter production facility that complies with GMP standards. The company's quality management system is regularly inspected by China's National Medical Products Administration (NMPA) and provincial authorities. The Recombinant Hepatitis B Vaccine is manufactured under stringent conditions, with in-process controls at every stage—from cell banking and fermentation to purification, formulation, and filling. Each batch undergoes comprehensive testing for potency (in vivo mouse assay), sterility, endotoxin, and residual impurities, ensuring consistent product quality.

With an annual capacity of 45 million doses, the company can support large-scale procurement and emergency supplies. The product is available in both single-dose and multi-dose vials, with a shelf life of 36 months when stored at 2-8°C. For international shipments, cold-chain logistics are rigorously maintained to guarantee product integrity.

Frequently Asked Questions

Q: What is the recommended vaccination schedule for this vaccine?

A: The standard schedule is three doses at 0, 1, and 6 months. For newborns of HBsAg-positive mothers, an accelerated schedule (0, 1, 2, 12 months) or an additional dose is recommended, along with hepatitis B immunoglobulin within 12 hours of birth.

Q: Can this vaccine be co-administered with other childhood vaccines?

A: Yes, it can be administered simultaneously with DTP, polio, Hib, and other routine childhood vaccines at separate sites. There is no interference with immune responses.

Q: What is the difference between the 10 µg and 20 µg formulations?

A: The 10 µg dose is sufficient for all age groups, including adults, due to the high immunogenicity of the Hansenula polymorpha platform. The 20 µg dose is sometimes used for dialysis patients or immunocompromised individuals, but our 10 µg product has shown excellent responses even in these populations, as evidenced by clinical data.

Q: How should the vaccine be stored and transported?

A: It should be stored at 2-8°C, protected from light, and never frozen. During transport, cold-chain integrity must be maintained using validated containers. The vaccine is stable for 36 months under these conditions.

Q: Does the vaccine contain any preservatives or animal-derived components?

A: No. The product is preservative-free and does not contain bovine serum albumin, antibiotics, or thiocyanate, making it safer for all recipients and reducing the risk of allergic reactions.

Q: What is the seroconversion rate after three doses?

A: In healthy individuals, the seroconversion rate (anti-HBs ≥10 mIU/mL) exceeds 98% after the full series. For neonates of carrier mothers, the efficacy is comparable, with protective titers achieved in over 95% of cases.

Partnering for Global Hepatitis Prevention

Choosing the right hepatitis B vaccine is a strategic decision with lasting public health impact. The Recombinant Hepatitis B Vaccine For Virus Infection Prevention offers a unique combination of advanced technology, proven immunogenicity, and exceptional safety, supported by two decades of real-world experience. AIM Honesty Biopharmaceutical Co., Ltd. stands ready to assist procurement agencies with comprehensive documentation, cold-chain support, and flexible packaging options. By partnering with AIM Honesty, you gain access to a reliable manufacturer with a track record of delivering high-quality vaccines to over 31 provinces and multiple countries. Contact our international sales team for technical data, sample requests, or to discuss customized supply arrangements.